Stifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Momentum Movers Trader Talk

JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)November 5, 2024 2:56 PM Form 10-Q Beam Therapeutics Inc. For: Sep 30November 5, 2024 9:06 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 9:00 AM Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ANovember 5, 2024 9:00 AM BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'November 5, 2024 8:58 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 8:31 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 7:05 AM Beam, Inc. (BEAM) Tops Q3 EPS by 1cNovember 5, 2024 6:39 AM Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNovember 5, 2024 6:30 AM